삼일제약

000520KOSPI의약품 제조업

40.1 / 100

Reference Date: 2026-06-10

Financial Score7.5 / 40

News Sentiment19.6 / 25

Momentum3.0 / 20

Disclosure10.0 / 15

AI Analysis: the high debt ratio poses financial risk, ROE is below the industry average. Plunged 21.8% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Samil Pharmaceutical, established in 1947, is a mid-sized pharmaceutical company specializing in ophthalmology, epilepsy, and digestive system drugs, with a business structure focused on original and generic drug development, production, and sales. In 2025, its consolidated sales reached 210.3 billion won, and it has secured domestic sales rights for NASH treatment 'Aramchol' and osteoarthritis treatment 'Lorecivivint', while also completing a global ophthalmology CMO plant in Vietnam.

Number of Employees

614people

Average Salary

67.8M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 11.934.0Point

PBR

1.16Industry Average 0.892.5Point

Higher than industry avg (caution)

ROE

-22.41Industry Average 4.010.0Point

Well below industry avg

Debt Ratio

39.90Industry Average 12.430.0Point

3.2x industry avg (risky)

Trend 2023~20251.0 / 10 points

Revenue Growth Rate

1.0 / 3

Avg ▲3.8% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼9923.9% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -8.3% (declining, 3yr)

Detailed News Sentiment

7 totalPositive 6Neutral 1Negative 0Average Sentiment Score 78.6

Positive
삼성바이오에피스, 아일리아 시밀러 '오퓨비즈' 유럽 출시
삼성바이오에피스의 아일리아 바이오시밀러 오퓨비즈 유럽 출시로 삼일제약과 직접 연관은 없으나, 관련 바이오 산업의 성장 기대감 증가.
Neutral
삼성바이오에피스, 유럽 직접판매 확대…'오퓨비즈' 출시
삼성바이오에피스의 유럽 직접판매 확대와 오퓨비즈 출시는 관련성이 낮아 삼일제약에 직접적인 영향이 제한적이다.
Positive
삼일제약, 美 점안제 전문기업과 북미 공략…월마트·CVS 입점
삼일제약이 미국 안과 전문 제약사와의 MOU 체결로 북미 시장 진출을 확대하여 긍정적인 성장 전망을 보임.

Detailed Momentum

52-week position1.0Point

Near 52w low (1%, downtrend)

Current 7,120Won52-week high 12,31052-week low 7,030

1-month return0.0Point

1m -21.84% (strong drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

10 totalPositive 0Neutral 10Negative 0

Neutral최대주주등소유주식변동신고서2026-06-08
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-06-05
Neutral최대주주등소유주식변동신고서2026-06-02
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-06-01
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-06-01